AP3B1
Basic information
Region (hg38): 5:77991640-78294762
Links
Phenotypes
GenCC
Source:
- Hermansky-Pudlak syndrome 2 (Strong), mode of inheritance: AR
- Hermansky-Pudlak syndrome 2 (Supportive), mode of inheritance: AR
- Hermansky-Pudlak syndrome 2 (Definitive), mode of inheritance: AR
- Hermansky-Pudlak syndrome 2 (Definitive), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Hermansky-Pudlak syndrome 2 | AR | Allergy/Immunology/Infectious; Dermatologic; Hematologic; Pulmonary | Prevention and treatment of bleeding episodes (eg, with DDAVP or platelet/RBC transfusions) can be effective, and aspirin-containing products should be avoided; Skin surveillance and protection can be beneficial; Prompt treatment of pulmonary infections (as well as avoidance of cigarette smoke) to maximize pulmonary function is indicated, including influenza and pneumococcus vaccination | Allergy/Immunology/Infectious; Dental; Dermatologic; Hematologic; Neurologic; Ophthalmologic; Pulmonary | 10024875; 11809908; 16507770; 16537806; 20301464; 23215637 |
ClinVar
This is a list of variants' phenotypes submitted to
- Hermansky-Pudlak syndrome 2 (23 variants)
- Autoinflammatory syndrome (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the AP3B1 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 123 | 131 | ||||
missense | 326 | 332 | ||||
nonsense | 12 | |||||
start loss | 0 | |||||
frameshift | 15 | 14 | 30 | |||
inframe indel | 5 | |||||
splice donor/acceptor (+/-2bp) | 11 | 14 | ||||
splice region | 16 | 24 | 3 | 43 | ||
non coding | 20 | 104 | 44 | 168 | ||
Total | 23 | 30 | 360 | 233 | 46 |
Highest pathogenic variant AF is 0.0000198
Variants in AP3B1
This is a list of pathogenic ClinVar variants found in the AP3B1 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
5-78002314-T-C | Hermansky-Pudlak syndrome | Likely benign (Jun 14, 2016) | ||
5-78002342-GTTTA-G | Hermansky-Pudlak syndrome | Uncertain significance (Jun 14, 2016) | ||
5-78002395-C-T | Hermansky-Pudlak syndrome 2 | Uncertain significance (Jan 12, 2018) | ||
5-78002420-G-A | Hermansky-Pudlak syndrome 2 | Uncertain significance (Jan 12, 2018) | ||
5-78002455-G-A | Hermansky-Pudlak syndrome 2 | Uncertain significance (Jan 13, 2018) | ||
5-78002522-C-G | Hermansky-Pudlak syndrome 2 | Uncertain significance (Jan 13, 2018) | ||
5-78002522-C-T | Hermansky-Pudlak syndrome 2 | Uncertain significance (Jan 13, 2018) | ||
5-78002523-T-C | Hermansky-Pudlak syndrome 2 | Benign (Jan 13, 2018) | ||
5-78002711-G-C | Hermansky-Pudlak syndrome 2 | Uncertain significance (Jan 13, 2018) | ||
5-78002761-A-G | Hermansky-Pudlak syndrome 2 | Uncertain significance (Jan 12, 2018) | ||
5-78002795-A-T | Hermansky-Pudlak syndrome • not specified | Benign (Nov 12, 2023) | ||
5-78002801-A-G | Hermansky-Pudlak syndrome 2 | Uncertain significance (Jan 13, 2018) | ||
5-78002832-G-GA | Hermansky-Pudlak syndrome | Uncertain significance (Jun 14, 2016) | ||
5-78002858-C-T | Hermansky-Pudlak syndrome 2 | Benign (Jan 13, 2018) | ||
5-78002861-T-C | Likely benign (Nov 10, 2018) | |||
5-78002901-G-T | AP3B1-related disorder | Likely benign (Feb 09, 2021) | ||
5-78002905-C-T | Hermansky-Pudlak syndrome 2 | Likely benign (Nov 15, 2023) | ||
5-78002922-G-C | Hermansky-Pudlak syndrome 2 | Uncertain significance (Mar 25, 2020) | ||
5-78002923-C-T | Hermansky-Pudlak syndrome 2 | Likely benign (Aug 02, 2023) | ||
5-78002933-C-T | Hermansky-Pudlak syndrome 2 | Uncertain significance (Jan 28, 2022) | ||
5-78002950-A-T | Hermansky-Pudlak syndrome 2 | Likely benign (Feb 06, 2020) | ||
5-78002957-G-A | Hermansky-Pudlak syndrome 2 • Autoinflammatory syndrome • Inborn genetic diseases | Uncertain significance (Apr 09, 2024) | ||
5-78002961-T-C | Hermansky-Pudlak syndrome 2 | Uncertain significance (Jan 03, 2022) | ||
5-78002964-C-T | Uncertain significance (Feb 20, 2024) | |||
5-78002973-T-C | Hermansky-Pudlak syndrome 2 | Uncertain significance (Jul 21, 2023) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
AP3B1 | protein_coding | protein_coding | ENST00000255194 | 27 | 294231 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.615 | 0.385 | 125715 | 0 | 33 | 125748 | 0.000131 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.890 | 508 | 568 | 0.895 | 0.0000277 | 7198 |
Missense in Polyphen | 81 | 122.78 | 0.65969 | 1523 | ||
Synonymous | 1.37 | 172 | 197 | 0.875 | 0.00000975 | 2073 |
Loss of Function | 5.63 | 13 | 60.1 | 0.216 | 0.00000312 | 742 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000364 | 0.000360 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.00 | 0.00 |
Finnish | 0.000140 | 0.000139 |
European (Non-Finnish) | 0.000133 | 0.000132 |
Middle Eastern | 0.00 | 0.00 |
South Asian | 0.000229 | 0.000163 |
Other | 0.000163 | 0.000163 |
dbNSFP
Source:
- Function
- FUNCTION: Subunit of non-clathrin- and clathrin-associated adaptor protein complex 3 (AP-3) that plays a role in protein sorting in the late-Golgi/trans-Golgi network (TGN) and/or endosomes. The AP complexes mediate both the recruitment of clathrin to membranes and the recognition of sorting signals within the cytosolic tails of transmembrane cargo molecules. AP-3 appears to be involved in the sorting of a subset of transmembrane proteins targeted to lysosomes and lysosome-related organelles. In concert with the BLOC-1 complex, AP-3 is required to target cargos into vesicles assembled at cell bodies for delivery into neurites and nerve terminals.;
- Disease
- DISEASE: Hermansky-Pudlak syndrome 2 (HPS2) [MIM:608233]: A form of Hermansky-Pudlak syndrome, a genetically heterogeneous autosomal recessive disorder characterized by oculocutaneous albinism, bleeding due to platelet storage pool deficiency, and lysosomal storage defects. This syndrome results from defects of diverse cytoplasmic organelles including melanosomes, platelet dense granules and lysosomes. Ceroid storage in the lungs is associated with pulmonary fibrosis, a common cause of premature death in individuals with HPS. HPS2 differs from the other forms of HPS in that it includes immunodeficiency in its phenotype and patients with HPS2 have an increased susceptibility to infections. {ECO:0000269|PubMed:10024875}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Lysosome - Homo sapiens (human);miR-targeted genes in lymphocytes - TarBase;miR-targeted genes in muscle cell - TarBase;Golgi Associated Vesicle Biogenesis;Clathrin derived vesicle budding;Disease;trans-Golgi Network Vesicle Budding;Vesicle-mediated transport;Membrane Trafficking;Signaling by BRAF and RAF fusions;Oncogenic MAPK signaling;Diseases of signal transduction
(Consensus)
Recessive Scores
- pRec
- 0.316
Intolerance Scores
- loftool
- 0.483
- rvis_EVS
- 0.43
- rvis_percentile_EVS
- 77.29
Haploinsufficiency Scores
- pHI
- 0.353
- hipred
- Y
- hipred_score
- 0.544
- ghis
- 0.493
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.824
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Ap3b1
- Phenotype
- growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); craniofacial phenotype; homeostasis/metabolism phenotype; cellular phenotype; renal/urinary system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; hematopoietic system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); reproductive system phenotype; pigmentation phenotype; limbs/digits/tail phenotype; hearing/vestibular/ear phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); vision/eye phenotype; immune system phenotype;
Gene ontology
- Biological process
- protein targeting to lysosome;intracellular protein transport;blood coagulation;anterograde axonal transport;synaptic vesicle budding from endosome;melanosome organization;antigen processing and presentation, exogenous lipid antigen via MHC class Ib;anterograde synaptic vesicle transport;positive regulation of NK T cell differentiation
- Cellular component
- lysosomal membrane;Golgi apparatus;membrane;AP-3 adaptor complex;clathrin adaptor complex;clathrin-coated vesicle membrane;postsynapse;axon cytoplasm
- Molecular function
- protein phosphatase binding;GTP-dependent protein binding